<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00771056</url>
  </required_header>
  <id_info>
    <org_study_id>08-088</org_study_id>
    <nct_id>NCT00771056</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine in Untreated B-CLL Patients</brief_title>
  <official_title>Phase II Study to Evaluate the Tolerability and Efficacy of Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients With Hydroxychloroquine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eligible CLL patients who sign an informed consent will be started on hydroxychloroquine
      400mg po daily for up to one year. They will be monitored for disease status as well as
      adverse reactions after two weeks and then every 4 weeks. Ophthalmologic exams is required at
      baseline and every 6 months or sooner if the patient develops any visual disturbances.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label, single arm Phase 2 study evaluating the feasibility, and
      efficacy of treating CLL subjects with hydroxychloroquine. The study schema and schedule of
      events are as follows:

      Prior to beginning hydroxychloroquine:

        -  Blood samples to be taken.

        -  Baseline tests confirming diagnosis of CLL as defined above (if not already obtained in
           records)

        -  Physical exam performed

        -  Either six months prior or 4 weeks within starting HCQ ophthalmologic exam documented

        -  Days 1-365 subject takes hydroxychloroquine 400mg/day

        -  At 2 weeks: CBC and chemistry

        -  Every 4 weeks: CBC, chemistry, history (including the inquiry about the presence or
           absence of visual symptoms) and physical exam.

        -  Starting at 4 weeks: blood samples taken for laboratory companion studies taken at
           office visit every 8 weeks.

        -  At 6 months (+ or - 30 days): subject will have follow up ophthalmologic exam). This
           will also be done in the presence of any visual/ocular symptoms.

      All subjects must meet the selection criteria for registration in this study. All subjects
      must have a peripheral blood sample submitted. It is estimated that approximately 70 subjects
      will be screened. The anticipated accrual period is 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    study suspended while data is reviewed for safety and efficacy.
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Response</measure>
    <time_frame>1 yr</time_frame>
    <description>Percentage of participants with a reduction of the absolute lymphocytic count- ALC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Next Treatment</measure>
    <time_frame>1 yr</time_frame>
    <description>number of months to time from last HCQ dose to next CLL treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>B-Cell Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine 400 mg po daily for up to one year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>400mg by mouth daily x 1 year</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <other_name>Plaquenil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Flow cytometry confirmed B-CLL

          -  No prior chemotherapy or immunotherapy

          -  Performance status 0-2

          -  Age &gt; 18 years old

          -  If childbearing age, woman you must be willing to use birth control for length of
             hydroxychloroquine use

          -  Must have capacity to consent for study and sign consent form

          -  Asymptomatic CLL not requiring treatment at time of study entry

        Exclusion Criteria:

          -  Pregnancy

          -  Significant optic nerve pathology as documented by an opthalmologic exam

          -  Hypersensitivity to 4-aminoquinoline compound

          -  Patients taking cardiac glycosides and cyclosporine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kanti R Rai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NSLIJ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center CLL Research and Treatment Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2008</study_first_submitted>
  <study_first_submitted_qc>October 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2008</study_first_posted>
  <results_first_submitted>December 17, 2015</results_first_submitted>
  <results_first_submitted_qc>June 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 26, 2016</results_first_posted>
  <last_update_submitted>August 18, 2016</last_update_submitted>
  <last_update_submitted_qc>August 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Kanti Rai, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>untreated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to contact each individual patient (participant in the trial) and inform hem/her of results of this trial as it affects each one of them.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was from April 2009 through termination December 2011. Patients were identified and enrolled in the CLL Research and Treatment Program where they already were being seen for care of their CLL.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Hydroxychloroquine</title>
          <description>Hydroxychloroquine 400 mg po daily for up to one year.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hydroxychloroquine</title>
          <description>Hydroxychloroquine 400 mg po daily for up to one year.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="44" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Response</title>
        <description>Percentage of participants with a reduction of the absolute lymphocytic count- ALC</description>
        <time_frame>1 yr</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydroxychloroquine</title>
            <description>Hydroxychloroquine 400 mg po daily for up to one year.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response</title>
          <description>Percentage of participants with a reduction of the absolute lymphocytic count- ALC</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Next Treatment</title>
        <description>number of months to time from last HCQ dose to next CLL treatment</description>
        <time_frame>1 yr</time_frame>
        <population>only analyzed for participants that were treated within one year post last dose of hydroxychloroquine dose</population>
        <group_list>
          <group group_id="O1">
            <title>Hydroxychloroquine</title>
            <description>Hydroxychloroquine 400 mg po daily for up to one year.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Next Treatment</title>
          <description>number of months to time from last HCQ dose to next CLL treatment</description>
          <population>only analyzed for participants that were treated within one year post last dose of hydroxychloroquine dose</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="2" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event reporting wil be reported if applicable as subjects are monitored on a monthly basis.</time_frame>
      <desc>Subjects were monitored monthly by physician for adverse events from hydroxychloroquine.</desc>
      <group_list>
        <group group_id="E1">
          <title>Hydroxychloroquine</title>
          <description>Hydroxychloroquine 400 mg po daily for up to one year.
Hydroxychloroquine: 400mg by mouth daily x 1 year</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kanti R Rai, MD</name_or_title>
      <organization>Northwell Health (formerly North Shore LIJ Health System)</organization>
      <phone>(718)470-4050</phone>
      <email>krai@nshs.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

